Strategic Initiative
Slingshot members are tracking this corporate initiative:
Zogenix (ZGNX) acquiring Modis Therapeutics for its late-stage investigational medicine targeting Thymidine Kinase 2 deficiency (TK2d) that has received FDA Breakthrough Therapy and EMA PRIME designations
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ZGNX |
|
|
Modis Therapeutics |
|
|
|
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Sep 26, 2019 Projected Implementation: Q3, 2019 Relevance Tracked Until: Q4, 2019
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Tk2d Candidate, Breakthrough Therapy Designation
